 This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 HER-2 positive metastatic breast cancer. Frequency, characteristics and severity of adverse events AE and serious adverse events SAE were followed to evaluate the safety of Herceptin in patients with HER2 positive metastatic breast cancer. 